Stock Movers: Costco, Crowdstrike, Chewy (Podcast)

Chewy shares fell as much as 8.8% after management said consumers look more "stretched" than earlier in the year, signaling softer demand conditions. Costco was highlighted favorably on market share and defensive spending trends, but Oppenheimer trimmed fiscal Q3 EPS expectations to $4.75 versus $4.98 consensus due to higher fuel costs and mix pressure ahead of May 28 results. CrowdStrike hit a new all-time high on fresh bullish analyst commentary.

Analysis

The near-term winner is CRWD, but the more important read-through is that security software remains one of the few enterprise spend buckets still protected even as broader IT budgets normalize. New highs here typically force systematic and fundamental managers to chase, which can extend momentum for days to weeks, but the setup is vulnerable if the next earnings print shows any deceleration in net new ARR or a softer billings profile. A crowded quality-growth trade means upside can continue mechanically even without a new fundamental step-up, but that also raises the odds of a sharp air pocket on any disappointment.

CHWY’s weakness looks less like a company-specific collapse and more like an early warning on discretionary pet spend elasticity after a long period of resilience. If management is describing consumers as more stretched now than earlier in the year, the second-order risk is mix shift away from premium food, autoship add-ons, and higher-margin discretionary categories toward lower-ticket essentials. That dynamic matters for suppliers and adjacent pet retailers because it usually shows up first in basket size before it appears in unit volume, so the revenue deceleration can be more persistent than headline traffic trends imply.

COST is the cleanest relative winner on a 3-6 month horizon because membership/value positioning tends to capture share when households trade down, but the margin setup is less forgiving than the equity story suggests. Fuel inflation and a heavier mix of low-margin e-commerce/pharmacy can quietly compress operating leverage even if comparable sales stay healthy, which creates a classic quality-versus-earnings setup into the print. The market may be underestimating how much of the stock’s multiple support depends on flawless execution rather than simply stable demand.

The contrarian angle is that the day’s move may be overconfident in assuming every high-quality retailer and software leader can stay insulated from a slower consumer/enterprise tape. The best risk-adjusted expression is not directional beta but relative value: long the company with durable wallet-share gains and short the name where the market is still paying for growth that is becoming more elastic. The key catalyst window is the next 1-8 weeks, with CHWY sensitive to any additional consumer commentary and COST to results on May 28; CRWD’s upside is more technical until the next fundamental checkpoint.

Key Decisions for Investors

• Long CRWD on momentum continuation for 1-3 weeks; use tight risk controls because new highs can extend another 5-8% but can retrace fast if sentiment or guidance softens.
• Short CHWY for 2-6 weeks as a consumer-demand fade trade; thesis improves if management repeats cautious commentary and the stock breaks prior support, with downside risk to another low-double-digit move.
• Pair trade: long COST / short CHWY into the next month to express trade-down winners vs. discretionary softness; better risk-adjusted than outright long retail beta.
• Buy COST put spreads into the May 28 earnings window if the stock re-rates higher into the print; looking for margin disappointment rather than sales weakness as the primary catalyst.
• For more tactical exposure, fade CRWD only on failed breakout days rather than initiating a naked short; momentum names can stay extended longer than fundamentals justify.